AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

• The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

AbbVie (NYSE:ABBV) told shareholders astatine its yearly gathering that 2025 was “another fantabulous year” for the company, citing grounds sales, stronger-than-expected gross and continued concern successful its cause pipeline and concern development.

Rob Michael, AbbVie’s president and main enforcement officer, said the institution delivered full nett revenues of $61.2 billion, exceeding its archetypal expectations by much than $2 billion. Adjusted net per stock were $10.54, supra the company’s archetypal guidance midpoint excluding the interaction of in-process probe and improvement expense.

→ Light Speed Returns: Corning Cashes In connected NVIDIA Growth

• MarketBeat Week successful Review – 04/27 - 05/01

Michael said AbbVie’s income maturation of 8.6% drove an all-time precocious for revenue, surpassing the company’s erstwhile highest by much than $3 cardinal contempt astir $16 cardinal of U.S. Humira erosion since nonaccomplishment of exclusivity.

“This has besides fueled a important summation successful our adjusted R&D investment, afloat backing astir 90 objective programs presently successful development,” Michael said.

Shareholders Elect Directors, Reject Governance Proposals

→ Years successful the Making, AMD’s Upside Movement Has Just Begun

• AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie said proxies representing much than 87% of shares entitled to ballot were received, establishing a quorum for the meeting. The institution presented 5 concern items: the predetermination of Class II directors, ratification of Ernst & Young arsenic auditor, an advisory ballot connected enforcement compensation, a absorption connection to destruct supermajority voting and a shareholder connection seeking an autarkic committee chair.